Talcum Powder Lawsuit: Settlement Status, Jury Verdicts, and Filing

A talcum powder lawsuit is a product liability claim alleging that Johnson & Johnson’s talc-based Baby Powder caused ovarian cancer or mesothelioma. More than 67,600 cases are now consolidated in a federal multidistrict litigation in New Jersey, three attempts by Johnson & Johnson to resolve the claims through bankruptcy have been dismissed, and as of June 2026 there is no global settlement. Individual trials continue, court-ordered mediation is underway, and people with a qualifying diagnosis and documented talc use can still file.

Where the Litigation Stands in 2026

The bulk of federal cases sit in Multidistrict Litigation No. 2738 in the U.S. District Court for the District of New Jersey, before Judge Michael A. Shipp.¹ As of May 2026, roughly 67,600 lawsuits were pending in that MDL.² Counting state court filings and cases not yet consolidated, the total exceeds 90,000.³

Two developments in 2025 reshaped the MDL. In early 2026, retired U.S. District Judge Freda Wolfson, serving as special master, recommended that juries be permitted to hear expert testimony linking talc use to ovarian cancer across the consolidated cases.⁴ And in August 2025, Judge Shipp ruled that plaintiffs could add Kenvue (Johnson & Johnson’s consumer health spinoff), Holdco, and Janssen as defendants in the master complaint.⁵ Kenvue owns the Baby product lines; Johnson & Johnson has agreed to indemnify Kenvue for talc liability under SEC filings.⁶

Court-ordered mediation began in September 2025, with Fouad Kurdi of Resolutions LLC serving as official mediator. The court directed both sides to negotiate in good faith and instructed plaintiffs’ attorneys to gather victim input.⁷ Further settlement discussions were scheduled for April 2026.⁴ No resolution has been announced.

What the Lawsuits Claim

Plaintiffs pursue two theories. The first is that women who used talc-based powder in the genital area for years absorbed particles that traveled through the reproductive tract to the ovaries, causing chronic inflammation and cancer. The second is that talc from certain mines was contaminated with asbestos fibers, and that inhaling those fibers during normal use of the powder caused mesothelioma, an aggressive cancer of the lining of the lungs or abdomen.

The science is contested. The International Agency for Research on Cancer classifies genital talc use as “probably carcinogenic to humans.” Case-control studies have reported a modest increased risk of ovarian cancer among regular users of genital talc, while prospective cohort studies have not consistently shown a significant overall increase.⁸ On mesothelioma, research has confirmed that talc from certain regions contained asbestos and that those fibers could accumulate in lung tissue after repeated inhalation.⁹

Johnson & Johnson has consistently maintained that its talc products are safe, do not contain asbestos, and do not cause cancer. The company stopped selling talc-based Baby Powder in the United States and Canada in 2020 and discontinued the product worldwide in 2023, calling both decisions commercial rather than safety-related.¹⁰

Why There Is No Global Settlement

Johnson & Johnson tried three times to route the litigation through Chapter 11 bankruptcy using a maneuver called the “Texas Two-Step”: create a subsidiary, load it with talc liabilities, and file that subsidiary for bankruptcy so the filing automatically stays every lawsuit while a settlement trust is proposed. All three failed.

The first attempt, filed in October 2021 through a new entity called LTL Management LLC, was dismissed when the Third Circuit ruled in January 2023 that LTL was not in financial distress. Johnson & Johnson refiled almost immediately in April 2023 with a $30 billion funding commitment. That case was dismissed in July 2023 on the same grounds, and the Third Circuit affirmed.¹¹

The third try came in September 2024 through a subsidiary called Red River Talc LLC, filed in the U.S. Bankruptcy Court for the Southern District of Texas. Johnson & Johnson claimed more than 83% of voting claimants supported a proposed settlement worth roughly $8 billion to $9 billion. After a two-week trial in February 2025, Bankruptcy Judge Christopher M. Lopez issued a 57-page opinion on March 31, 2025, rejecting the plan and dismissing the case. He found three fatal problems:

Voting irregularities. Plaintiffs’ law firms had cast tens of thousands of votes without direct client authorization. One firm switched 11,000 “no” votes to “yes” with less than two days’ notice to clients. The court called the pre-filing solicitation process “fundamentally flawed and rushed.”¹²
Impermissible third-party releases. Applying the Supreme Court’s June 2024 decision in Harrington v. Purdue Pharma, Judge Lopez ruled that the plan improperly sought to release claims against hundreds of non-debtors, including retailers and Kenvue, without claimant consent.¹³
No legitimate reorganization purpose. Red River Talc had no ongoing operations or employees, making it a poor candidate for bankruptcy protection.¹⁴

The Purdue Pharma decision, issued 5–4 on June 27, 2024, held that the Bankruptcy Code does not authorize nonconsensual releases of claims against non-debtors.¹⁵ That ruling gutted the legal foundation of the Two-Step strategy. Johnson & Johnson did not appeal the Red River dismissal and announced it would return to the tort system, reversing about $7 billion it had reserved for the bankruptcy resolution.¹⁶ Bloomberg Intelligence analysts have estimated the company’s total exposure could reach $11 billion.²

What Juries Have Been Awarding

With bankruptcy off the table, verdicts from individual trials are shaping the pressure on both sides. The largest historical verdict is a 2018 St. Louis award of $4.69 billion to 22 women who alleged ovarian cancer from talc use, including $550 million in compensatory damages and $4.14 billion in punitive damages. A Missouri appellate court later upheld about $2.12 billion for 20 of the original plaintiffs.⁴

Recent trials have kept producing large numbers, particularly in mesothelioma cases:

December 2025, Baltimore: a jury awarded over $1.5 billion, including $59.84 million in compensatory damages, to a single peritoneal mesothelioma plaintiff, the largest individual verdict in the litigation’s history.²
December 2025, California: a bellwether jury awarded $40 million to two women for ovarian cancer.²
October 2025, California: a $966 million verdict for the family of an 88-year-old woman who died of mesothelioma was reduced to $16 million after a judge vacated the $950 million punitive portion, finding insufficient evidence of malice or knowing concealment.³
July 2025, Boston: about $42 million to a 69-year-old man with mesothelioma.²
May 2026, Minnesota: $10.2 million to a 43-year-old man whose mesothelioma was linked to asbestos-laced talc in body powder.¹⁷
February 2026, Pennsylvania: $250,000 to the family of a woman who died of ovarian cancer, illustrating how far outcomes can spread.⁴

Mesothelioma verdicts alone reached $320 million in 2024 and exceeded $2.5 billion in 2025, according to one litigation tracker.³ Johnson & Johnson has pointed to prevailing in 16 of 17 ovarian cancer cases tried over the past 11 years as its rationale for returning to individual litigation.¹⁶

Who Can Still File

Filing generally requires a confirmed diagnosis of ovarian cancer, mesothelioma, or a related cancer such as peritoneal cancer or invasive fallopian tube cancer, plus a documented history of regular use of talc-based products over years. Family members of a deceased person who met these criteria can bring wrongful death claims. Statutes of limitations vary by state but typically run two to three years from the date of diagnosis or the date the person discovered a potential link between the cancer and talc use.¹⁸

For ovarian cancer claims, the strongest cases tend to involve daily talc use in the genital area for at least four years, a pathology report showing talc particles in tumor tissue, and no genetic predisposition (such as a BRCA-1 mutation) that independently explains the cancer. For mesothelioma claims, the key is showing that asbestos exposure came from contaminated talc products rather than from workplace or industrial sources.¹⁹

What to Expect Next

The first federal MDL bellwether trial, Judkins v. Johnson & Johnson, involves a New Hampshire woman who alleges decades of talc use caused her ovarian cancer. The case was selected in July 2025 and is expected to influence Johnson & Johnson’s settlement posture across the MDL, though it had not yet gone to trial as of mid-2026.²⁰ The Philadelphia Court of Common Pleas has established a separate mass tort program for ovarian cancer claims, with bellwether trials scheduled for 2026.⁴

If a global settlement eventually forms, legal industry estimates suggest individual payouts could run from $100,000 to $1 million for ovarian cancer claims and from $500,000 to over $2 million for mesothelioma claims, depending on the type of cancer, the claimant’s age, medical costs, and jurisdiction.² These are projections, not offers, and they only apply if a deal is reached; claimants pursuing individual trials face a much wider range of outcomes, from multi-million-dollar verdicts to defense wins.

Anyone considering a claim should confirm their state’s deadline quickly, gather medical records establishing the diagnosis, and document the product usage history before contacting counsel. The window is defined by state law, not by the pace of the MDL.

1
U.S. District Court, District of New Jersey. Johnson & Johnson Talcum Powder Litigation
2
Drugwatch. Talcum Powder Settlements
3
Sokolove Law. Talcum Powder Lawsuits
4
Lawsuit Information Center. $2 Billion Verdict in Missouri Motivates J&J to Settle Talcum Powder Lawsuits
5
New Jersey Law Journal. MDL Judge Allows Talc Plaintiffs to Sue Additional Johnson & Johnson Affiliates
6
Levy Konigsberg. Levy Konigsberg Files 116 Mesothelioma Suits Against Kenvue
7
Sokolove Law. Talcum Powder Lawsuit Updates
8
American Cancer Society. Talcum Powder and Cancer
9
National Library of Medicine. Cosmetic Talc as a Cause of Mesothelioma
10
CNBC. J&J to Stop Selling Talc-Based Baby Powder Globally in 2023
11
Columbia Business Law Review. Johnson & Johnson Texas Two-Step Bankruptcy
12
Bailey Glasser. In re Red River Talc LLC Memorandum Decision and Order
13
American Bankruptcy Institute. Bankruptcy Court Dismisses Chapter 11 Plan Over Voting Irregularities
14
Bailey Glasser. BG Wins Dismissal of Johnson and Johnson Third Bankruptcy
15
Supreme Court of the United States. Harrington v. Purdue Pharma L.P.
16
Johnson & Johnson. Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
17
Law.com. Jury Awards $10.2M Verdict in Case Tying Cancer to Asbestos-Laced Talc
18
The Lanier Law Firm. Talc Ovarian Cancer Lawsuit
19
Pintas & Mullins. Can I File a Talcum Powder Lawsuit
20
Darrow. Johnson and Johnson Talc Lawsuit